Prescott Group Capital Management L.L.C. Has $2.01 Million Position in Emergent BioSolutions Inc. (NYSE:EBS)

Prescott Group Capital Management L.L.C. boosted its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 250.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 210,000 shares of the biopharmaceutical company’s stock after acquiring an additional 150,000 shares during the period. Prescott Group Capital Management L.L.C.’s holdings in Emergent BioSolutions were worth $2,008,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of EBS. Jacobs Levy Equity Management Inc. bought a new position in shares of Emergent BioSolutions in the 3rd quarter worth $1,547,000. Oak Hill Advisors LP bought a new position in Emergent BioSolutions during the third quarter worth about $9,296,000. Barclays PLC grew its position in shares of Emergent BioSolutions by 361.6% during the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 30,792 shares during the period. Geode Capital Management LLC increased its stake in shares of Emergent BioSolutions by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock valued at $4,861,000 after acquiring an additional 25,776 shares during the last quarter. Finally, Stifel Financial Corp acquired a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $96,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Stock Performance

Shares of EBS opened at $5.84 on Friday. The firm has a market cap of $316.22 million, a P/E ratio of -1.42 and a beta of 1.62. Emergent BioSolutions Inc. has a twelve month low of $1.82 and a twelve month high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm’s 50 day moving average price is $9.38 and its two-hundred day moving average price is $9.00.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.40. The business had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period in the previous year, the firm posted ($0.77) EPS. On average, analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on EBS shares. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday. Benchmark boosted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.